Baseline and early changes in neutrophil-lymphocyte ratio as a prognostic biomarker with 177Lu-PSMA-617 therapy in advanced prostate cancer
Ronit Juthani, Caiwei Zhong, Ali Tarhini, Miguel Muniz, Wanling Xie, Hailey Stoltenberg, Andrew Wolanski, Jolivette Ritzer, Xiao X. Wei, Heather Jacene, Daniel S. Childs, Praful Ravi Prostate Cancer and Prostatic Diseases
· Springer Nature
· 2026-11-14
· DOI: 10.1038/s41391-026-01173-w
Аннотация
Prostate Cancer and Prostatic Diseases, Published online: 14 November 2026; doi:10.1038/s41391-026-01173-w Baseline and early changes in neutrophil-lymphocyte ratio as a prognostic biomarker with 177 Lu-PSMA-617 therapy in advanced prostate cancer
Ronit Juthani, Caiwei Zhong, Ali Tarhini, Miguel Muniz, Wanling Xie, Hailey Stoltenberg et al. Baseline and early changes in neutrophil-lymphocyte ratio as a prognostic biomarker with 177Lu-PSMA-617 therapy in advanced prostate cancer. // Prostate Cancer and Prostatic Diseases. – 2026. – DOI: 10.1038/s41391-026-01173-w. – URL: https://www.nature.com/articles/s41391-026-01173-w
Ronit Juthani, Caiwei Zhong, Ali Tarhini, Miguel Muniz, Wanling Xie, Hailey Stoltenberg, Andrew Wolanski, Jolivette Ritzer, Xiao X. Wei, Heather Jacene, Daniel S. Childs, & Praful Ravi (2026). Baseline and early changes in neutrophil-lymphocyte ratio as a prognostic biomarker with 177Lu-PSMA-617 therapy in advanced prostate cancer. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-026-01173-w
Ronit Juthani, et al. “Baseline and early changes in neutrophil-lymphocyte ratio as a prognostic biomarker with 177Lu-PSMA-617 therapy in advanced prostate cancer.” Prostate Cancer and Prostatic Diseases, 2026. doi:10.1038/s41391-026-01173-w.
@article{Juthani2026,
title = {Baseline and early changes in neutrophil-lymphocyte ratio as a prognostic biomarker with 177Lu-PSMA-617 therapy in advanced prostate cancer},
author = {Juthani, Ronit and Zhong, Caiwei and Tarhini, Ali and Muniz, Miguel and Xie, Wanling and Stoltenberg, Hailey and Wolanski, Andrew and Ritzer, Jolivette and Wei, Xiao X. and Jacene, Heather and Childs, Daniel S. and Ravi, Praful},
journal = {Prostate Cancer and Prostatic Diseases},
year = {2026},
doi = {10.1038/s41391-026-01173-w},
url = {https://www.nature.com/articles/s41391-026-01173-w}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...